Navigation Links
PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum
Date:10/19/2009

BOSTON, Oct. 19 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address important industry issues at the Drug Information Association (DIA) 3rd Annual Clinical Forum, being held from October 19 - 21, 2009 in Nice, France. A number of PAREXEL's thought leaders will present on topics ranging from pharmacovigilance reporting to centralized monitoring for late phase trials. Presentations from PAREXEL and its subsidiary, Perceptive Informatics, a leading eClinical solutions provider, will also discuss best practices for the integration of technology in post-marketing studies as well as data checks in Electronic Patient-Reported Outcomes (ePRO) based studies.

Attendees at the meeting will be able to learn more about capabilities related to these topics by visiting the PAREXEL Booth #16 or Perceptive Informatics Booth #13 in the exhibit hall. The DIA Annual Clinical Forum program features the following sessions:

Monday, October 19

  • The European Annual Safety Report: A case study in best practice for outsourcing pharmacovigilance writing to a global CRO - Julia Cooper, PhD, Senior Director, Worldwide Head of Medical Writing Services, PAREXEL (4:00 p.m. - 5:30 p.m.)
  • Simple Data Checks to Check for Fraud Data: A case study on the process of fraud detection in ePRO studies - Hannah Jane O'Gorman, Associate Director, ePRO Operations, Perceptive Informatics (4:30 p.m. - 5:30 p.m.)

Wednesday, October 21

  • Centralized Monitoring in Late Phase Studies: Shifting the paradigm - Ramita Tandon, Senior Director, Global Portfolio Management, Peri-Approval Services, PAREXEL (9:00 a.m. - 10:30 a.m.)
  • The ICF: A balancing act - James Wolfe, Associate Director, Medical Writing Services Europe, PAREXEL (9:00 a.m. - 10:30 a.m.)
  • Integration of Technology in Post-Marketing Studies - Kate Trainor, Vice President, Operations, Peri-Approval Services, PAREXEL (11:00 a.m. - 12:30 p.m.)

For more information about PAREXEL visit www.PAREXEL.com or Booth #16, and for more information about Perceptive Informatics visit www.perceptive.com or Booth #13. Information about the meeting can be found at www.diahome.org.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has approximately 9,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended June 30, 2009 as filed with the SEC on August 28, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Contacts:
    Jennifer Baird, Senior Director         Gene Carozza/Kim Baker
     of Public Relations                    PAN Communications
    PAREXEL International                   Tel: +978-474-1900
    Tel: +781-434-4409                      Email: PAREXEL@pancomm.com
    Email: Jennifer.Baird@PAREXEL.com

SOURCE PAREXEL International Corporation


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
2. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
3. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
4. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
5. PAREXEL Reports Preliminary Second Quarter Results
6. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
7. PAREXEL Reports Second Quarter Fiscal Year 2009 Financial Results
8. PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil
9. PAREXEL International to Present at Raymond James 30th Annual Institutional Investors and the Barclays Capital Global Healthcare Conferences
10. PAREXEL Announces Date of Third Quarter Fiscal Year 2009 Earnings Release and Conference Call
11. PAREXEL Experts to Address Partnering Best Practices and Innovative Trial Design at Partnerships With CROs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... Levels of a protein in the blood associated with heart ... in the journal Radiology. , Heart disease and brain disease exact a major burden ... aging population. Damage to both organs often occurs at a subclinical stage, or before ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... ... high performance connectors, is now promoting to the US market its advanced highly ... ODU LAMTAC® and ODU TURNTAC®. These advanced technologies are ideal for a ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
(Date:12/7/2016)... ... 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering ... is launching a charity drive to raise funds that will benefit the Marine Corps ... marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... SAN DIEGO , Dec. 7, 2016   ... today announced that it has completed enrollment in the ... IP receptor agonist targeting the prostacyclin pathway for the ... approximately 60 patients at sites globally. "This ... and is evidence of our strategic focus on our ...
(Date:12/7/2016)... Dec. 7, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, and XAS ... services, visit diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the ...
(Date:12/7/2016)... Kan. , Dec. 7, 2016   Rx Savings ... West Virginia and its Public Employees Insurance Agency ... members access to their innovative healthcare software, ultimately saving money ... with PEIA and provide its members with access to our ... or a more effective, affordable therapy can be found," says ...
Breaking Medicine Technology: